Cyanidin-3-O-glucoside improves non-alcoholic fatty liver disease by promoting PINK1-mediated mitophagy in mice.
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
03
09
2019
revised:
16
04
2020
accepted:
17
04
2020
pubmed:
29
4
2020
medline:
22
6
2021
entrez:
29
4
2020
Statut:
ppublish
Résumé
Identifying safe and effective compounds that target to mitophagy to eliminate impaired mitochondria may be an attractive therapeutic strategy for non-alcoholic fatty liver disease. Here, we investigated the effects of cyanidin-3-O-glucoside (C3G) on non-alcoholic fatty liver disease (NAFLD) and the underlying mechanism. Non-alcoholic fatty liver disease was induced by a high-fat diet for 16 weeks. C3G was administered during the last 4 weeks. In vivo, recombinant adenoviruses and AAV8 were used for overexpression and knockdown of PTEN-induced kinase 1 (PINK1), respectively. AML-12 and HepG2 cells were used for the mechanism study. C3G administration suppressed hepatic oxidative stress, NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and steatosis and improved systemic glucose metabolism in mice with NAFLD. These effects of C3G were also observed in palmitic acid-treated AML-12 cells and hepatocytes from NAFLD patients. Mechanistic investigations revealed that C3G increased PINK1/Parkin expression and mitochondrial localization and promoted PINK1-mediated mitophagy to clear damaged mitochondria. Knockdown of hepatic PINK1 abolished the mitophagy-inducing effect of C3G, which blunted the beneficial effects of C3G on oxidative stress, NLRP3 inflammasome activation, hepatic steatosis and glucose metabolism. These results demonstrate that PINK1-mediated mitophagy plays an essential role in the ability of C3G to alleviate NAFLD and suggest that C3G may be a potential drug candidate for NAFLD treatment.
Sections du résumé
BACKGROUND AND PURPOSE
Identifying safe and effective compounds that target to mitophagy to eliminate impaired mitochondria may be an attractive therapeutic strategy for non-alcoholic fatty liver disease. Here, we investigated the effects of cyanidin-3-O-glucoside (C3G) on non-alcoholic fatty liver disease (NAFLD) and the underlying mechanism.
EXPERIMENTAL APPROACH
Non-alcoholic fatty liver disease was induced by a high-fat diet for 16 weeks. C3G was administered during the last 4 weeks. In vivo, recombinant adenoviruses and AAV8 were used for overexpression and knockdown of PTEN-induced kinase 1 (PINK1), respectively. AML-12 and HepG2 cells were used for the mechanism study.
KEY RESULTS
C3G administration suppressed hepatic oxidative stress, NLR family pyrin domain containing 3 (NLRP3) inflammasome activation and steatosis and improved systemic glucose metabolism in mice with NAFLD. These effects of C3G were also observed in palmitic acid-treated AML-12 cells and hepatocytes from NAFLD patients. Mechanistic investigations revealed that C3G increased PINK1/Parkin expression and mitochondrial localization and promoted PINK1-mediated mitophagy to clear damaged mitochondria. Knockdown of hepatic PINK1 abolished the mitophagy-inducing effect of C3G, which blunted the beneficial effects of C3G on oxidative stress, NLRP3 inflammasome activation, hepatic steatosis and glucose metabolism.
CONCLUSION AND IMPLICATIONS
These results demonstrate that PINK1-mediated mitophagy plays an essential role in the ability of C3G to alleviate NAFLD and suggest that C3G may be a potential drug candidate for NAFLD treatment.
Identifiants
pubmed: 32343398
doi: 10.1111/bph.15083
pmc: PMC7348088
doi:
Substances chimiques
Anthocyanins
0
Glucosides
0
cyanidin
7732ZHU564
Protein Kinases
EC 2.7.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3591-3607Subventions
Organisme : National Key Research and Development Program
ID : 2016YFD0501206
Organisme : National Natural Science Foundation of China
ID : 31672621
Organisme : National Natural Science Foundation of China
ID : 31772810
Organisme : Talents Cultivation Program
Organisme : China Postdoctoral Science Foundation
ID : 2019TQ0115
Organisme : China Postdoctoral Science Foundation
ID : 2019M661216
Informations de copyright
© 2020 The British Pharmacological Society.
Références
Cell. 2016 Feb 25;164(5):896-910
pubmed: 26919428
Nat Commun. 2019 Apr 5;10(1):1566
pubmed: 30952952
J Immunol. 2017 Apr 15;198(8):3283-3295
pubmed: 28275133
Nature. 2015 Aug 20;524(7565):309-314
pubmed: 26266977
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
J Med Food. 2007 Sep;10(3):552-6
pubmed: 17887951
Autophagy. 2014 Jan;10(1):155-64
pubmed: 24270884
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
Free Radic Biol Med. 2016 Nov;100:210-222
pubmed: 27094585
Free Radic Biol Med. 2012 Jan 15;52(2):314-27
pubmed: 22085656
J Nutr Biochem. 2004 Jan;15(1):2-11
pubmed: 14711454
J Clin Invest. 2015 Feb;125(2):521-38
pubmed: 25562319
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Cell Death Dis. 2014 Apr 17;5:e1179
pubmed: 24743734
Cell Rep. 2016 Mar 22;14(11):2611-23
pubmed: 26971994
Autophagy. 2009 Nov;5(8):1213-4
pubmed: 19786829
Annu Rev Cancer Biol. 2019 Mar;3:203-222
pubmed: 31650096
Gastroenterology. 2016 Feb;150(2):328-39
pubmed: 26453774
Nat Cell Biol. 2013 Jun;15(6):647-58
pubmed: 23604321
Hepatology. 2013 Oct;58(4):1497-507
pubmed: 23299992
Crit Rev Food Sci Nutr. 2017 Mar 4;57(4):834-855
pubmed: 25897647
Hepatology. 2011 Mar;53(3):810-20
pubmed: 21319198
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Liver Int. 2016 Jan;36(1):5-20
pubmed: 26436447
Nature. 2014 Dec 4;516(7529):112-5
pubmed: 25383539
J Hepatol. 2016 Apr;64(4):925-32
pubmed: 26639394
Gastroenterology. 2015 Aug;149(2):389-97.e10
pubmed: 25935633
Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106
pubmed: 29149325
J Nutr Biochem. 2012 Apr;23(4):349-60
pubmed: 21543211
Br J Pharmacol. 2015 Jul;172(14):3461-71
pubmed: 26114403
J Lipid Res. 2012 Sep;53(9):2002-13
pubmed: 22766885
PLoS One. 2015 Nov 10;10(11):e0142438
pubmed: 26555609
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Methods Mol Biol. 2005;290:207-29
pubmed: 15361665
Nature. 2009 Apr 30;458(7242):1131-5
pubmed: 19339967
J Dairy Sci. 2018 Oct;101(10):9544-9558
pubmed: 30100495
Hepatology. 2016 Dec;64(6):1994-2014
pubmed: 27637015
Br J Pharmacol. 2010 Aug;160(7):1577-9
pubmed: 20649561
Hepatol Commun. 2017 Jul;1(5):359-369
pubmed: 29109982
Hepatology. 2015 Feb;61(2):486-96
pubmed: 25203315
Nat Med. 2016 Sep;22(9):1002-12
pubmed: 27455510
Br J Pharmacol. 2020 Aug;177(15):3591-3607
pubmed: 32343398
Am J Physiol Gastrointest Liver Physiol. 2015 Sep 1;309(5):G324-40
pubmed: 26159696
Korean J Physiol Pharmacol. 2012 Aug;16(4):249-53
pubmed: 22915990
Br J Pharmacol. 2017 Sep;174(18):3032-3044
pubmed: 28646531
Cell Metab. 2010 Jun 9;11(6):467-78
pubmed: 20519119
Curr Opin Cell Biol. 2017 Apr;45:83-91
pubmed: 28437683
J Dairy Sci. 2018 Apr;101(4):3476-3487
pubmed: 29398030
Br J Pharmacol. 2018 Feb;175(3):407-411
pubmed: 29350411
Br J Pharmacol. 2017 Jul;174(14):2358-2372
pubmed: 28471490
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141
pubmed: 31710717
Br J Pharmacol. 2015 Jul;172(13):3189-93
pubmed: 25964986
Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12920-4
pubmed: 21768365